MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 571180 | Name: A 74273

Description:

WARNING: This product is for research use only, not for human or veterinary use.

A 74273 is a nonpeptidic and renin inhibitor. It may be used to treat cardiovascular diseases due to renin inhibition.

Chemical Structure

A 74273
A 74273
CAS#130316-95-9

Theoretical Analysis

MedKoo Cat#: 571180

Name: A 74273

CAS#: 130316-95-9

Chemical Formula: C44H74N4O8

Exact Mass: 786.5507

Molecular Weight: 787.10

Elemental Analysis: C, 67.14; H, 9.48; N, 7.12; O, 16.26

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
A 74273; A-74273; A74273
IUPAC/Chemical Name
6-cyclohexyl-4-hydroxy-2-isopropyl-5-((S)-2-(((S)-1-(4-(methoxymethoxy)piperidin-1-yl)-1-oxo-3-phenylpropan-2-yl)oxy)hexanamido)-N-(3-morpholinopropyl)hexanamide
InChi Key
NVMVSIUABPBQIL-UOKFUGOKSA-N
InChi Code
InChI=1S/C44H74N4O8/c1-5-6-18-40(56-41(30-35-16-11-8-12-17-35)44(52)48-23-19-36(20-24-48)55-32-53-4)43(51)46-38(29-34-14-9-7-10-15-34)39(49)31-37(33(2)3)42(50)45-21-13-22-47-25-27-54-28-26-47/h8,11-12,16-17,33-34,36-41,49H,5-7,9-10,13-15,18-32H2,1-4H3,(H,45,50)(H,46,51)/t37?,38?,39?,40-,41-/m0/s1
SMILES Code
CCCC[C@H](O[C@H](C(N1CCC(OCOC)CC1)=O)CC2=CC=CC=C2)C(NC(C(O)CC(C(NCCCN3CCOCC3)=O)C(C)C)CC4CCCCC4)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 787.10 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Verburg KM, Polakowski JS, Kovar PJ, Klinghofer V, Barlow JL, Stein HH, Mantei RA, Fung AK, Boyd SA, Baker WR, et al. Effects of high doses of A-74273, a novel nonpeptidic and orally bioavailable renin inhibitor. J Cardiovasc Pharmacol. 1993 Jan;21(1):149-55. PubMed PMID: 7678671. 2: Kleinert HD, Stein HH, Boyd S, Fung AK, Baker WR, Verburg KM, Polakowski JS, Kovar P, Barlow J, Cohen J, et al. Discovery of a well-absorbed, efficacious renin inhibitor, A-74273. Hypertension. 1992 Dec;20(6):768-75. PubMed PMID: 1452292. 3: Frishman WH, Fozailoff A, Lin C, Dike C. Renin inhibition: a new approach to cardiovascular therapy. J Clin Pharmacol. 1994 Sep;34(9):873-80. Review. PubMed PMID: 7983230. 4: Wessale JL, Calzadilla SV, Boyd SA, Baker WR, Stein HH, Kovar PJ, Barlow J, Klinghofer V, Mantei R, Kleinert HD. Cardiovascular effects and hemodynamic mechanism of action of the novel, nonpeptidic renin inhibitor A-74273 in dogs. J Cardiovasc Pharmacol. 1993 Oct;22(4):644-52. PubMed PMID: 7505369. 5: Denissen JF, Grabowski BA, Johnson MK, Boyd SA, Uchic JT, Stein H, Cepa S, Hill P. The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans. Drug Metab Dispos. 1994 Nov-Dec;22(6):880-8. PubMed PMID: 7895605. 6: Boyd SA, Fung AK, Baker WR, Mantei RA, Stein HH, Cohen J, Barlow JL, Klinghofer V, Wessale JL, Verburg KM, et al. Nonpeptide renin inhibitors with good intraduodenal bioavailability and efficacy in dog. J Med Chem. 1994 Sep 16;37(19):2991-3007. PubMed PMID: 7932521. 7: Dayton BD, Stein HH, Cohen J, Baker WR, Boyd SA, Condon SL, Donner BG, Fung AK, Luly JR, Rosenberg SH, et al. Effects of angiotensinase inhibitors on plasma protein binding and IC50 determinations of renin inhibitors. Clin Chem. 1992 Nov;38(11):2239-43. PubMed PMID: 1330373. 8: Rosenberg SH, Kleinert HD. Renin inhibitors. Pharm Biotechnol. 1998;11:7-28. Review. PubMed PMID: 9760674. 9: Boyd SA, Fung AK, Baker WR, Mantei RA, Armiger YL, Stein HH, Cohen J, Egan DA, Barlow JL, Klinghofer V, et al. C-terminal modifications of nonpeptide renin inhibitors: improved oral bioavailability via modification of physicochemical properties. J Med Chem. 1992 May 15;35(10):1735-46. PubMed PMID: 1588555.